NEU neuren pharmaceuticals limited

Ann: 2022 Annual Report to shareholders, page-7

  1. 2,516 Posts.
    lightbulb Created with Sketch. 686
    A very well run company. I like that the corporate costs are very reasonable given how well they have executed their plans that have been clearly communicated to investors. So many other ASX listed medical and biotech companies (I won't name names) seem to always dangle the stick of TAM, future profits and constantly raise money, increase operating costs without ever achieving goals that will bring the company closer to producing cashflow.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.85
Change
-0.110(0.85%)
Mkt cap ! $1.598B
Open High Low Value Volume
$12.82 $13.05 $12.53 $6.559M 511.8K

Buyers (Bids)

No. Vol. Price($)
1 1657 $12.83
 

Sellers (Offers)

Price($) Vol. No.
$12.85 6303 1
View Market Depth
Last trade - 16.10pm 17/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.